<DOC>
	<DOC>NCT00427999</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.</brief_summary>
	<brief_title>Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion criteria: Histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration). Patients must have increasing PSA levels (within 3 months prior to enrollment) with at least two consecutively increasing PSA levels. PSA value before inclusion must be at least 5 ng/ml At least 18 years of age. At least capable of self care and up of at least 50% of waking hours (ECOG performance status 0 2), adequate bone marrow function and lab results. Exclusion criteria: Change of hormone therapy within 6 weeks prior inclusion Prior chemotherapy Therapy with Imatinib, or therapy with other inhibitors of tyrosinkinase. Second neoplasm diagnosed within 5 years before study start. Patients who require therapy with warfarin Known diagnosis of HIV, hepatitis B, or hepatitis C infection. Severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency Surgical therapy within 4 weeks before inclusion. Prior therapy with isotopes strontium or rhenium. Radiation therapy to &gt; 25% of bone marrow within 4 weeks before inclusion. Treatment with other experimental substances within 30 days before study start. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hormone-refractory</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>multitargeted</keyword>
	<keyword>tyrosinkinase</keyword>
</DOC>